WO2008023362A3 - Traitement du cancer - Google Patents

Traitement du cancer Download PDF

Info

Publication number
WO2008023362A3
WO2008023362A3 PCT/IL2007/001009 IL2007001009W WO2008023362A3 WO 2008023362 A3 WO2008023362 A3 WO 2008023362A3 IL 2007001009 W IL2007001009 W IL 2007001009W WO 2008023362 A3 WO2008023362 A3 WO 2008023362A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
methotrexate
treatment
combination
a3ar agonist
Prior art date
Application number
PCT/IL2007/001009
Other languages
English (en)
Other versions
WO2008023362A2 (fr
Inventor
Pnina Fishman
Sara Bar-Yehuda
Original Assignee
Can Fite Biopharma Ltd
Pnina Fishman
Sara Bar-Yehuda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd, Pnina Fishman, Sara Bar-Yehuda filed Critical Can Fite Biopharma Ltd
Publication of WO2008023362A2 publication Critical patent/WO2008023362A2/fr
Publication of WO2008023362A3 publication Critical patent/WO2008023362A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

L'invention concerne le traitement thérapeutique d'un cancer par une administration combinée de méthotrexate et d'un agoniste du récepteur A3 de l'adénosine. L'invention concerne également des méthodes de traitement thérapeutique comprenant cette administration combinée, les compositions pharmaceutiques utiles dans ces procédés et aussi l'utilisation de n'importe lequel de ces agents actifs pour préparer cette composition pharmaceutique.
PCT/IL2007/001009 2006-08-21 2007-08-16 Traitement du cancer WO2008023362A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83886306P 2006-08-21 2006-08-21
US83886206P 2006-08-21 2006-08-21
US60/838,862 2006-08-21
US60/838,863 2006-08-21

Publications (2)

Publication Number Publication Date
WO2008023362A2 WO2008023362A2 (fr) 2008-02-28
WO2008023362A3 true WO2008023362A3 (fr) 2008-07-03

Family

ID=38578621

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2007/001009 WO2008023362A2 (fr) 2006-08-21 2007-08-16 Traitement du cancer

Country Status (1)

Country Link
WO (1) WO2008023362A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2694983A1 (fr) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Traitements de troubles proliferatifs des lymphocytes b
ES2531828T3 (es) 2008-03-31 2015-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Derivados de purina como agonistas selectivos de los receptores A3 de adenosina
US8916570B2 (en) 2008-03-31 2014-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor agonists and antagonists
US9181253B2 (en) 2008-08-01 2015-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists, partial agonists, and antagonists
AU2009276411B2 (en) * 2008-08-01 2014-08-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists and partial agonists
EP2331543A4 (fr) * 2008-09-26 2013-06-19 Agency Science Tech & Res Dérivés 3-désazanéplanocine
EP2456419B1 (fr) 2009-07-21 2016-11-23 Oradin Pharmaceutical Ltd. Ligands du récepteur a3 adenosine pour la modulation de la pigmentation
KR101181627B1 (ko) * 2009-12-17 2012-09-10 이화여자대학교 산학협력단 Ａ3 아데노신 수용체 효능제를 포함하는 전립선암 치료용 약제학적 조성물
KR101192063B1 (ko) 2010-02-02 2012-10-17 이화여자대학교 산학협력단 염증성 질환의 예방 및 치료용 약제학적 조성물
US20120322815A1 (en) * 2009-12-17 2012-12-20 Ewha University-Industry Collaboration Foundation Pharmaceutical composition containing a3 adenosine receptor agonist
KR101192097B1 (ko) 2009-12-17 2012-10-18 이화여자대학교 산학협력단 Ａ3 아데노신 수용체 효능제를 포함하는 대장암 치료용 약제학적 조성물
KR101207755B1 (ko) * 2010-02-02 2012-12-03 이화여자대학교 산학협력단 염증성 질환의 예방 및 치료용 약제학적 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019360A2 (fr) * 1999-09-10 2001-03-22 Can-Fite Biopharma Ltd. Compositions pharmaceutiques contenant un antagoniste ou un agoniste de recepteur d'adenosine
WO2004038006A2 (fr) * 2002-10-25 2004-05-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nucleosides puriques
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
WO2006031505A1 (fr) * 2004-09-09 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives de purine comme agonistes du recepteur d'adenosine a3 et a1
WO2006034190A2 (fr) * 2004-09-20 2006-03-30 Inotek Pharmaceuticals Corporation Dérivés de la purine et leurs procédés d'utilisation
WO2006059328A1 (fr) * 2004-12-02 2006-06-08 Can-Fite Biopharma Ltd. Traitement anti-inflammatoire

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019360A2 (fr) * 1999-09-10 2001-03-22 Can-Fite Biopharma Ltd. Compositions pharmaceutiques contenant un antagoniste ou un agoniste de recepteur d'adenosine
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
WO2004038006A2 (fr) * 2002-10-25 2004-05-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nucleosides puriques
WO2006031505A1 (fr) * 2004-09-09 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives de purine comme agonistes du recepteur d'adenosine a3 et a1
WO2006034190A2 (fr) * 2004-09-20 2006-03-30 Inotek Pharmaceuticals Corporation Dérivés de la purine et leurs procédés d'utilisation
WO2006059328A1 (fr) * 2004-12-02 2006-06-08 Can-Fite Biopharma Ltd. Traitement anti-inflammatoire

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FISHMAN P ET AL: "The anti-cancer effect of A3 adenosine receptor agonists: A novel, targeted therapy", IMMUNOLOGY, ENDOCRINE AND METABOLIC AGENTS IN MEDICINAL CHEMISTRY 200708 NL, vol. 7, no. 4, August 2007 (2007-08-01), pages 298 - 303, XP008089962, ISSN: 1871-5222 *
JOSHI BHALCHANDRA V ET AL: "Purine derivatives as ligands for A(3) adenosine receptors", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 5, no. 13, 2005, pages 1275 - 1295, XP008089968, ISSN: 1568-0266 *
PARFITT, K.: "Martindale, The complete drug reference, Thrity-second edition", 1999, PHARMACEUTICAL PRESS, LONDON, UK, XP002478059 *

Also Published As

Publication number Publication date
WO2008023362A2 (fr) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2008023362A3 (fr) Traitement du cancer
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
WO2007008752A3 (fr) Compositions pharmaceutiques a liberation prolongee pour medicaments tres solubles dans l'eau
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2007092620A3 (fr) Formulations stables et leurs procedes de preparation et d'utilisation
WO2007149406A8 (fr) Polypeptides facteurs ix de la coagulation modifiés et leur utilisation thérapeutique
WO2008039218A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2005112633A3 (fr) Composes et compositions pour administration d’agents actifs
HK1128471A1 (en) Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents
WO2012027065A3 (fr) Polythérapie pour traiter des maladies
CL2007002708A1 (es) Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
CA3094580C (fr) Formulations orales d'analogues de cytidine et leurs procedes d'utilisation
WO2008105773A3 (fr) Système pour l'administration ciblée d'agents thérapeutiques
IL196775A (en) Annotations 4,2-Bis (3-Methyl-Morpholine-4-Yl) -7-Phenyl-Pyrido [3,2- d] Pyrimidine, Containing and Using Pharmaceuticals as Drugs and Drug Manufacturing
WO2008131056A3 (fr) Préparations monoeximiques a libération soutenue d'analgésiques opioïdes et non opioïdes
EP2056818A4 (fr) Compositions et méthodes de neuroprotection
CL2007002513A1 (es) Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
WO2009109927A3 (fr) Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2007035783A3 (fr) Preparations combinees d'analogues de cytidine et d'agents platine
MX2009010689A (es) Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales.
EP2142549A4 (fr) Dérivés d'adénosine, procédé pour la synthèse de ces derniers, et compositions pharmaceutiques pour la prévention et le traitement de maladies inflammatoires contenant lesdits dérivés en tant qu'ingrédients actifs
EP1845099A4 (fr) Dérivés d'artémisine (qinghaosu), méthodes de synthèse et applications, et préparations pharmaceutiques contenant lesdits dérivés
IL207928A (en) Pharmacotherapeutic agent that contains an active drug (mtx) and helps 2, 2-anhydropyrimidine to reduce and use mtx toxicity
WO2009088673A3 (fr) Composition pharmaceutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07805482

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07805482

Country of ref document: EP

Kind code of ref document: A2